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Vaginal progesterone prophylaxis for preterm birth 
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double-blind trial
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Alex McConnachie, Stavros Petrou, Neil J Sebire, Tina Lavender, Sonia Whyte, John Norrie, for the OPPTIMUM study group
Summary
Background Progesterone administration has been shown to reduce the risk of preterm birth and neonatal morbidity 
in women at high risk, but there is uncertainty about longer term eﬀ ects on the child.
Methods We did a double-blind, randomised, placebo-controlled trial of vaginal progesterone, 200 mg daily taken 
from 22–24 to 34 weeks of gestation, on pregnancy and infant outcomes in women at risk of preterm birth (because 
of previous spontaneous birth at ≤34 weeks and 0 days of gestation, or a cervical length ≤25 mm, or because of a 
positive fetal ﬁ bronectin test combined with other clinical risk factors for preterm birth [any one of a history in a 
previous pregnancy of preterm birth, second trimester loss, preterm premature fetal membrane rupture, or a history 
of a cervical procedure to treat abnormal smears]). The objective of the study was to determine whether vaginal 
progesterone prophylaxis given to reduce the risk of preterm birth aﬀ ects neonatal and childhood outcomes. We 
deﬁ ned three primary outcomes: fetal death or birth before 34 weeks and 0 days gestation (obstetric), a composite of 
death, brain injury, or bronchopulmonary dysplasia (neonatal), and a standardised cognitive score at 2 years of age 
(childhood), imputing values for deaths. Randomisation was done through a web portal, with participants, 
investigators, and others involved in giving the intervention, assessing outcomes, or analysing data masked to 
treatment allocation until the end of the study. Analysis was by intention to treat. This trial is registered at ISRCTN.
com, number ISRCTN14568373.
Findings Between Feb 2, 2009, and April 12, 2013, we randomly assigned 1228 women to the placebo group (n=610) 
and the progesterone group (n=618). In the placebo group, data from 597, 587, and 439 women or babies were 
available for analysis of obstetric, neonatal, and childhood outcomes, respectively; in the progesterone group the 
corresponding numbers were 600, 589, and 430. After correction for multiple outcomes, progesterone had no 
signiﬁ cant eﬀ ect on the primary obstetric outcome (odds ratio adjusted for multiple comparisons [OR] 0·86, 95% CI 
0·61–1·22) or neonatal outcome (OR 0·62, 0·38–1·03), nor on the childhood outcome (cognitive score, progesterone 
group vs placebo group, 97·3 [SD 17·9] vs 97·7 [17·5]; diﬀ erence in means –0·48, 95% CI –2·77 to 1·81). Maternal or 
child serious adverse events were reported in 70 (11%) of 610 patients in the placebo group and 59 (10%) of 616 patients 
in the progesterone group (p=0·27).
Interpretation Vaginal progesterone was not associated with reduced risk of preterm birth or composite neonatal 
adverse outcomes, and had no long-term beneﬁ t or harm on outcomes in children at 2 years of age. 
Funding Eﬃ  cacy and Mechanism Evaluation (EME) Programme, a Medical Research Council (MRC) and National 
Institute for Health Research (NIHR) partnership. The EME Programme is funded by the MRC and NIHR, with 
contributions from the Chief Scientist Oﬃ  ce in Scotland and National Institute for Social Care and Research in Wales.
Copyright © Norman et al. Open Access article distributed under the terms of CC BY.
Introduction
Several studies have assessed either vaginal progesterone 
or intramuscular 17α-hydroxyprogesterone caproate for 
the prevention of preterm birth in asymptomatic women 
with singleton pregnancy at high risk of preterm birth. 
An individual patient data meta-analysis of women with 
a short cervix showed that vaginal progesterone reduced 
the risk of preterm birth before 33 weeks (relative risk 
[RR] 0·58, 95% CI 0·42–0·80) and reduced a composite 
of neonatal mortality and morbidity (RR 0·57, 
0·40–0·81).1 Although there is debate whether vaginal 
and intramuscular therapies have similar mechanisms 
or eﬃ  cacy, the Cochrane Library meta-analysis groups 
the two treatments together, but reports separately for 
diﬀ erent maternal risk groups.2 Reduced risk of preterm 
birth before 34 weeks was shown in women with a short 
cervix (RR 0·64, 95% CI 0·45–0·90), without eﬀ ect 
on perinatal mortality or neonatal death (perinatal 
mortality RR 0·74, 0·42–1·29; neonatal death RR 0·55, 
0·26–1·13).2 By contrast, in women with previous 
preterm birth, progestogens reduced the incidence of 
preterm birth (RR 0·31, 95% CI 0·14–0·69), perinatal 
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mortality and neonatal death.2 Although intramuscular 
17α-hydroxyprogesterone caproate is licensed for women 
with a previous preterm birth, an independent analysis 
of data on vaginal progesterone for a US Food and Drug 
Administration advisory panel showed no beneﬁ t, with 
the panel concluding that “the overall risk/beneﬁ t proﬁ le 
[is] not acceptable” to support approval of vaginal 
progesterone in women with a short cervix.3
Despite recommendations for progesterone use4 there 
are few data on long-term beneﬁ t or safety for the baby 
beyond the neonatal period. Adverse childhood eﬀ ects of 
preterm birth include neurodevelopmental and cognitive 
impairments, and increase with degree of prematurity.5 
Progesterone, by delaying birth and reducing prematurity, 
might reduce risk of impairment, but this could be oﬀ set 
by direct fetal harm by continuing prolonged exposure to 
intrauterine infection or inﬂ ammation, commonly 
associated with preterm labour. Furthermore, therapies 
applied in pregnancy might have diﬀ ering eﬀ ects in the 
neonatal period and early childhood (beneﬁ t in one and 
harm in another), as shown in the ORACLE II trial of 
antibiotics in spontaneous preterm labour6,7 and in trials 
of multiple doses of corticosteroids.8 Hence, further 
information on childhood outcomes following 
progesterone treatment is required to determine the 
risk–beneﬁ t ratio of this therapy.
Research in context
Evidence before this study
Vaginal progesterone administration has been shown to reduce 
the risk of preterm birth and neonatal morbidity in women at 
high risk, but there is uncertainty about longer term eﬀ ects on 
the child. We searched the Cochrane Pregnancy and Childbirth 
Group’s Trials Register and the Cochrane Central Register of 
Controlled Trials (the Cochrane Library) until Feb 4, 2016, on 
MEDLINE (Jan 1, 1996, to Feb 4, 2016), and PubMed (Jan 1, 
1974, to Feb 4, 2016) using the terms “progesterone/
progestogen” AND “preterm birth prevention” AND 
“randomised trial” with no language restrictions. We also 
searched reference lists of trials and other review articles 
identiﬁ ed from this initial search and from our records. We 
excluded women with multiple pregnancy and those with 
symptoms of preterm labour. We identiﬁ ed two systematic 
reviews that compared preterm birth rates, neonatal outcomes, 
or childhood outcomes in women treated with progesterone or 
progestogens compared with those treated with placebo: a 
conventional meta-analysis published by the Cochrane 
collaboration  and an individual patient data meta-analysis. No 
additional randomised trials were identiﬁ ed which were not 
included in the Cochrane review. Neither of the meta-analyses 
reported on our three primary outcomes, those of fetal death or 
delivery, either occurring before 34 weeks and 0 days of 
gestation (obstetric primary outcome); a composite of death, 
bronchopulmonary dysplasia, and brain injury on cerebral 
ultrasound (neonatal primary outcome); or the Bayley-III 
cognitive composite score at 22–26 months of chronological age 
(childhood primary outcome). One individual patient data 
meta-analysis of women with a short cervix reported the eﬀ ect 
of vaginal progesterone on the outcomes of preterm birth before 
33 weeks (relative risk [RR] 0·58, 95% CI 0·42–0·80), and on a 
composite of neonatal mortality and morbidity (RR 0·57, 
0·40–0·81). This individual patient data meta-analysis was 
restricted to women treated with vaginal progesterone. The 
Cochrane Library meta-analysis grouped women treated with 
any progestogen and reported on risk of preterm birth before 
34 weeks review for women with a short cervix (RR 0·64, 95% CI 
0·45–0·90), and on perinatal mortality (RR 0·74, 0·42–1·29) or 
neonatal death (RR 0·55, 0·26–1·13). Regarding women with a 
previous preterm birth, the Cochrane Library reported that 
progestogens reduced the incidence of preterm birth (RR 0·31, 
95% CI 0·14–0·69), and both perinatal mortality (RR 0·50, 
0·33–0·75) and neonatal death (RR 0·45, 0·27–0·76). Neither the 
individual patient data meta-analysis nor the Cochrane review 
were able to report on childhood outcomes, with the Cochrane 
review noting that  “there is limited information available 
relating to longer-term infant and childhood outcomes, the 
assessment of which remains a priority”.
Added value of this study
The OPPTIMUM study is, to our knowledge, the largest study to 
compare obstetric, neonatal, and childhood outcomes in 
high-risk women with singleton pregnancy treated with vaginal 
progesterone to prevent preterm birth. It is one of the few studies 
to look at childhood eﬀ ects. In OPPTIMUM, by contrast with 
some of the published literature, vaginal progesterone was not 
signiﬁ cantly associated with reduced risk either of preterm birth 
or of composite neonatal adverse outcomes. Additionally, 
progesterone had no signiﬁ cant long-term beneﬁ t or harm on 
outcomes in children at 2 years of age. The primary outcomes 
reported in OPPTIMUM were diﬀ erent from the outcomes 
reported in the meta-analyses described above (and indeed 
diﬀ erent from the primary outcomes in the source studies), hence 
meta-analysis of the evidence to provide a meaningful pooled 
estimate was not possible. We plan an individual patient data 
level analysis that will be able to address complexities such as 
diﬀ erent inclusion criteria for the studies, diﬀ erent progestogens 
used (vaginal progesterone or 17α-hydroxyprogesterone 
caproate), and the diﬀ erences in outcome reporting.  
Implications of all the available evidence
The ﬁ ndings from OPPTIMUM are diﬀ erent to some of those 
reported in the literature. For the ﬁ rst time, we show childhood 
outcomes of progesterone to prevent preterm birth. The results 
of OPPTIMUM should prompt a major review of the use of 
progesterone for preterm birth prophylaxis, a search to identify 
speciﬁ c women who might speciﬁ cally beneﬁ t, and a 
redoubling of eﬀ orts to ﬁ nd alternative strategies to prevent 
preterm birth in women at risk.
Articles
2108 www.thelancet.com   Vol 387   May 21, 2016
Therefore, we did a double-blind randomised trial to 
determine whether vaginal progesterone prophylaxis 
given to reduce the risk of preterm birth aﬀ ects neonatal 
and childhood outcomes.
Methods
Study design and participants
OPPTIMUM (dOes Progesterone Prophylaxis To prevent 
preterm labour IMprove oUtcoMe?) is a multicentre 
randomised double-blind placebo-controlled trial. 
Women were recruited from 65 UK National Health 
Service hospitals and one Swedish hospital. An 
abbreviated protocol has been published.9
The study was granted approval by the Scotland A 
Research Ethics Committee (reference 08/MRE00/6). 
Clinical trials authorisation was given by the Medicines and 
Healthcare products Regulatory Agency (MHRA reference 
22931/0009/001-0001 later revised to 01384/0208/001). A 
trial steering committee and a Data Monitoring Committee 
supervised the conduct of the study (appendix).
The study comprised a screening phase at 18–24 weeks 
and 0 days gestation and a treatment phase, starting at 
between 22 and 24 weeks of gestation. Written informed 
consent was obtained for both the screening phase (at 
18–24 weeks and 0 days gestation) and treatment phase 
(between 22 and 24 weeks gestational age). All women 
had a singleton pregnancy, with gestational age 
established by ultrasound scan before 16 weeks, and were 
16 years or older at screening. Women with clinical risk 
factors for preterm birth (any of a history in a previous 
pregnancy of preterm birth, or second trimester loss, or 
preterm premature fetal membrane rupture, or any 
history of a cervical procedure to treat abnormal smears) 
and a positive fetal ﬁ bronectin test at 22–24 weeks of 
gestation were eligible for random allocation in the 
treatment phase from the beginning of the trial, and 
designated ﬁ bronectin positive. After analysis of 
preliminary (masked) data in July, 2010, and the 
publication of a systematic review on screening for 
preterm birth,10 we realised that our initial selection 
strategy erroneously missed women at medium-to-high 
risk of preterm birth. Thus, from Sept 1, 2010, after 
recruitment of the initial 84 women, ﬁ bronectin-negative 
women with a history of spontaneous preterm birth at 
34 weeks or less of gestation, or a cervical length of 
25 mm or less were also eligible for inclusion, and 
designated a ﬁ bronectin-negative group (see appendix 
for detailed inclusion and exclusion criteria and 
ﬁ bronectin-positive or ﬁ bronectin-negative group 
allocation). There are no nationally agreed 
recommendations on which pregnant women should be 
screened for preterm birth risk by measuring cervical 
length, nor did the OPPTIMUM protocol include 
recommendations on who should undergo cervical 
length screening, hence any such measurements were 
made by clinicians on an individual patient basis before 
the woman’s recruitment to OPPTIMUM. A cervical 
length of 25 mm or less at any time between 18 and 
24 weeks and 0 days gestation in the index pregnancy 
conferred eligibility for recruitment.
Randomisation and masking
Eligible women were allocated (1:1) to either 
progesterone 200 mg soft capsules (Utrogestan, Besins 
Healthcare) or an identical appearing placebo. 
Assignment to treatment allocation was done through a 
web portal hosted by the study data centre at the 
Robertson Centre for Biostatistics, at the Glasgow 
Clinical Trials Unit, University of Glasgow. The 
randomisation schedule was computer-generated at the 
Robertson Centre, using the method of randomised 
permuted blocks of length four, stratiﬁ ed by history of a 
previous pregnancy of more than 14 weeks of gestation 
and by study centre. Allocation concealment was 
achieved by use of a placebo, which appeared identical 
to the active drug. Participants were asked for informed 
consent and enrolled by collaborating clinicians (listed 
in this Article and the appendix), who used the web 
portal described above to randomly assign participants 
to treatment. Treatment allocation corresponded to a 
box number in the local pharmacy, containing either 
active or placebo drug. Participants, investigators, 
pharmacists, and others involved in giving the 
intervention, assessing outcomes, or analysing data 
remained masked to treatment allocation until the end 
of the study. There was no formal attempt made to 
assess the success of masking.
Procedures
The participant administered the vaginal study medication 
daily at bedtime, commencing from about 22–24 weeks of 
gestation until 34 weeks or delivery of the baby, whichever 
was sooner. Co-administration of bromocriptine, rifamycin, 
ketoconazole, or ciclosporin was prohibited due to potential 
drug interactions. Rules for individual women to stop 
treatment on safety grounds (eg, after development of 
symptomatic placenta praevia) are deﬁ ned in the protocol. 
Compliance (assessed for each woman using a 
combination of medication pack returns, patient diaries, 
and patient self-reports) was calculated as the percentage 
of doses of study medication used divided by the expected 
doses. Adequate compliance was taken as 80% of 
prescribed medication.
Data were collected at screening, randomisation, 34 weeks 
of gestation, during labour and delivery, during the neonatal 
stay and at 1 and 2 years post-delivery to determine clinical 
outcomes. 2 year assessments, based on chronological age 
because of the mixed term and preterm population, were 
done at the local hospital clinic or at home. This assessment 
comprised the parent-completed structured clinical history, 
a parent-completed behavioural measure (the Strengths 
and Diﬃ  culties Questionnaire) and the cognitive scale of 
the Bayley Scales of Infant and Toddler Development 3rd 
Edition (Bayley-III). All assessments were undertaken by 
See Online for appendix
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assessors who had received training, either from the study 
centre or via a national course; all met prespeciﬁ ed criteria 
of 90% agreement or more on an item-by-item basis with an 
independent psychologist. Record forms were checked 
centrally for consistency and completeness. For children for 
whom we could not arrange a clinic assessment we 
requested information from the family doctor concerning 
general health and the presence of motor, sensory, and 
developmental concerns. 
Outcomes
We deﬁ ned three primary outcomes: either fetal death or 
delivery occurring before 34 weeks and 0 days of gestation 
(obstetric outcome); a composite of death, broncho-
pulmonary dysplasia, and brain injury on cerebral 
ultrasound (neonatal outcome); and the Bayley-III 
cognitive composite score at 22–26 months of 
chronological age (childhood outcome).
Brain injury was deﬁ ned as any intraventricular 
haemorrhage (excluding subependymal haemorrhages), 
parenchymal cystic lesion or haemorrhagic lesion, 
or persistent ventriculomegaly (ventricular index 
>97th percentile). All scans were reported locally. All 
abnormal scans and 10% of normal scans were reviewed 
centrally masked to the local report (NM). 
Bronchopulmonary dysplasia (severe chronic lung 
disease) was deﬁ ned as need for at least 30% oxygen or 
positive pressure (positive pressure ventilation or nasal 
continuous positive airway pressure) at 36 weeks 
postmenstrual age or discharge, whichever came ﬁ rst.
Secondary eﬃ  cacy and safety outcomes were as follows: 
gestational age at delivery (weeks); deaths up to 2 years of 
age; death after trial entry up to the end of study; daily 
category of care after delivery room (normal or special or 
high dependency or intensive); surfactant administration; 
suspected or conﬁ rmed necrotising entercolitis; neonatal 
infections (one or more discrete episodes with positive 
blood culture among those with infection, one or more 
discrete episodes with positive CNS culture among those 
with infection); maternal or child serious adverse events 
during pregnancy and birth; composite outcome of death 
or moderate-to-severe neurodevelopmental impairment at 
2 years; moderate-to-severe neurodevelopmental impair-
ment; individual components of disability; admissions to 
hospital during follow-up; behavioural scale scores at 
2 years assessed in strengths and diﬃ  culties questionnaire; 
change in EuroQol 5D (EQ-5D) from baseline to birth; 
change in EQ-5D from baseline to 12 months; and 
women’s perception of treatment 1 month post-delivery 
(the proportion extremely or fairly satisﬁ ed). Outcomes 
were categorised as moderate or severe using 
published deﬁ nitions.11
Statistical analysis
A statistical analysis plan was ﬁ nalised before data lock. 
Statistical analyses were done by C-MM and AM at the 
Robertson Centre for Biostatistics, Glasgow University 
according to the intention-to-treat principle. The three 
primary outcomes and secondary outcomes were 
compared between the treatment groups using mixed 
Figure: Trial proﬁ le
*Randomised in error, ineligible for treatment, and excluded post-randomisation. †Consent withdrawals for each 
of the phases refer to consent withdrawal at any time before reaching the outcome for that phase. ‡Losses to 
follow-up for each of the phases refer to losses to follow-up at any time before reaching the outcome for that 
phase. §Numbers with missing outcome data refer to each speciﬁ c outcome only (obstetric, neonatal, and 
childhood) and are not additive across the stages since women can have outcome data for a later outcome.
15 132 patient records assessed for eligibility
8724 excluded from eligibility screening visit
1540 not approached 
6014 declined to participate before screening visit
1170 failed to attend eligibility screening visit 
6408 attended eligibility screening visit  
575 excluded from fibronectin test screening phase
510 declined participation
53 ineligible
12 did not have fibronectin test
5833 eligible women tested with fibronectin 
in the screening phase
4605 excluded from randomisation
3461 ineligible (negative fibronectin, no other 
risk factor)
1144 eligible but not randomly assigned
1228 patients randomly assigned
618 allocated to progesterone
163 fibronectin positive
453 fibronectin negative
2 unknown fibronectin status
610 allocated to placebo
181 fibronectin positive
429 fibronectin negative
2 withdrawn before initiating 
treatment* 
45 withdrew consent after
initiating treatment† 
10 obstetric
3 neonatal
32 childhood 
116 lost to follow-up‡
6 obstetric
110 childhood
  8 missing neonatal outcome 
data only§
  25 missing childhood outcome 
data only§
597 analysed in the obstetric phase 
587 analysed in the neonatal phase
439 analysed in the childhood phase 
600 analysed in the obstetric phase
589 analysed in the neonatal phase
430 analysed in the childhood phase 
42 withdrew consent after
initiating treatment† 
10 obstetric
8 neonatal
24 childhood 
100 lost to follow-up‡
2 obstetric
1 neonatal 
97 childhood
1 missing obstetric outcome 
data only§
 2 missing neonatal outcome
data only§
29 missing childhood  outcome 
data only§
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eﬀ ects logistic regression (or, for continuous variables, 
linear regression) models including treatment allocation 
and previous pregnancy (≥14 weeks) as ﬁ xed eﬀ ects, with 
study centre as a random eﬀ ect. According to the 
prespeciﬁ ed statistical analysis plan, p values were initially 
reported without adjustment for multiple comparisons, 
then adjusted using a Bonferroni-Holm procedure.12 The 
planned sample size was around 1125 participants, 
depending on the relative numbers of fetal ﬁ bronectin-
positive and fetal ﬁ bronectin-negative women recruited.9 
Detailed sample size calculations are available in the 
published protocol, but in brief the study had at least 80% 
power to detect what was considered the minimal 
important clinical diﬀ erence for each of the three primary 
outcomes at a nominal 5% level of signiﬁ cance.9
Sensitivity analyses included repeating the primary 
analyses in a per-protocol dataset (which excluded data 
from women who were found not to be compliant with the 
inclusion or exclusion criteria, or who had a structural or 
chromosomal fetal anomaly discovered after inclusion, or 
who had a multiple pregnancy discovered after inclusion 
or who were not adequately compliant with treatment by 
the prespeciﬁ ed deﬁ nition), and the use of multiple 
imputation of missing primary outcome data. Preplanned 
subgroup analyses for primary outcomes were done by 
extending the main regression models to include 
interaction terms for the following subgroups: ﬁ bronectin 
positive or ﬁ bronectin negative, cervical length of at most 
25 mm or longer than 25 mm, cervical length of at most 
15 mm or longer than 15 mm, chorioamnionitis yes or no, 
history of spontaneous preterm birth or no such history, 
and history of preterm birth or no such history. Safety 
outcomes (adverse events) were assessed in a safety 
population, excluding women for whom it was documented 
that no study medication was taken. This trial is registered 
with ISRCTN.com, number ISRCTN14568373.
Role of the funding source
Neither the funders of the study nor the provider of active 
and placebo medication had any role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. C-MM and AM had full access to all 
the data in the study and JEN had ﬁ nal responsibility for 
the decision to submit for publication. 
Results
We reviewed the case notes of 15 132 women for eligibility, 
between Feb 2, 2009, and April 12, 2013. 1228 (8%) were 
subsequently randomly assigned, 610 allocated to placebo 
and 618 to progesterone (ﬁ gure). Two of these women 
were randomised in error and were excluded from 
initiating on treatment and the intention-to-treat 
population. Baseline characteristics of participants in the 
intention-to-treat population were balanced across the 
two allocated groups (table 1). The number of women 
randomly assigned per site ranged from one to 165; three 
sites screened but did not randomly assign participants. 
Information on the obstetric, neonatal, and childhood 
primary outcomes was available for 1197 (97%), 
1176 (96%), and 869 (71%) of participants, respectively. 
There were few diﬀ erences in baseline characteristics 
between those for whom primary outcome data was or 
was not available (appendix).
Information from diary returns for 1011 (82%) women 
showed 80% or more compliance in 361 (71%) of 509 in 
the placebo group and 333 (66%) of 502 in the 
progesterone group. For compliant women, the median 
percentage of medication taken was 92·3% 
(IQR 71·6–98·7) and 92·9% (59·0–98·6), respectively. 
No woman terminated treatment because of prespeciﬁ ed 
discontinuation rules.
Although the point estimate of the odds ratio (OR) was 
in the direction of beneﬁ t, administration of progesterone 
did not signiﬁ cantly alter the risk of the obstetric (fetal 
death or birth before 34 weeks) or neonatal (a composite of 
death, brain injury, or bronchopulmonary dysplasia) 
Placebo group Progesterone group
N n (%) or mean (SD) N n (%) or mean (SD)
Age (years) 610 31·4 (5·8) 615 31·5 (5·6)
Smoking 607 125 (21%) 613 111 (18%)
Alcohol 609 34 (6%) 614 29 (5%)
Drug use 609 9 (1%) 614 8 (1%)
Years in full-time education 568 13·5 (3·0) 554 13·5 (3·1)
Ethnic group
White 609 446 (73%) 615 449 (73%)
Black 609 95 (16%) 615 85 (14%)
Asian 609 51 (8%) 615 53 (9%)
Mixed 609 12 (2%) 615 16 (3%)
Other 609 5 (1%) 615 12 (2%)
Height (cm) 607 163·6 (6·4) 614 163·5 (6·7)
Weight (kg) 607 71·4 (16·7) 614 71·9 (17·5)
Body-mass index (kg/m²) 607 26·7 (6·1) 614 26·9 (6·4)
Systolic blood pressure (mm Hg) 608 112·4 (12·2) 611 111·3 (12·5)
Diastolic blood pressure (mm Hg) 608 66·2 (8·6) 611 65·7 (8·5)
Any previous pregnancy 609 581 (95%) 615 591 (96%)
Previous pregnancy of at least 14 weeks 609 571 (94%) 615 578 (94%)
History of preterm birth (any) 608 473 (78%) 615 493 (80%)
History of spontaneous preterm birth 598 448 (75%) 605 473 (78%)
History of livebirth followed by 
neonatal death
609 85 (14 %) 615 80 (13%)
History of stillbirth 609 48 (8%) 615 47 (8%)
Cervical length 351 28·8 (11·1) 361 28·2 (10·6)
Cervical length ≤25 mm 351 119 (34%) 361 137 (38%)
Cervical length ≤15 mm 351 47 (13%) 361 51 (14%)
Fibronectin testing in screening phase
Gestation (weeks) at ﬁ bronectin test 610 22·9 (0·6) 615 22·9 (0·6)
Positive ﬁ bronectin test result 610 180 (30%) 615 163 (27%)
Continuous variables are mean (SD), categorical variables are n (%).
Table 1: Demographics and baseline characteristics of women entered into the treatment phase of the 
OPPTIMUM study
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Placebo group Progesterone group Unadjusted odds ratio 
(95% CI) or diﬀ erence in 
means (95% CI)
p value 
(unadjusted)
Adjusted odds ratio 
(95% CI)* or diﬀ erence 
in means (95% CI)
p value 
(adjusted*)
Fetal death or delivery <34 weeks of gestation 108/597 (18%) 96/600 (16%) 0·86 (0·64 to 1·17) 0·34 0·86 (0·61 to 1·22) 0·67
Neonatal morbidity or death 60/587 (10%) 39/589 (7%) 0·62 (0·41 to 0·94) 0·02 0·62 (0·38 to 1·03) 0·072
Cognitive composite score at 2 years†‡ 97·7 (17·5) 97·3 (17·9) –0·48 (–2·77 to 1·81)§ 0·68 –0·48 (–2·77 to 1·81)§ 0·68
Components of the obstetric outcome
Fetal death 7/597 (1%) 8/600 (1%) 1·14 (0·41 to 3·17) 0·8 ·· ··
Liveborn delivery before 34 weeks 101/590 (17%) 88/592 (15%) 0·85 (0·62 to 1·15) 0·29 ·· ··
Components of the neonatal outcome
Neonatal death 6/597 (1%) 1/600 (<1%) 0·17 (0·06 to 0·49) 0·0009¶ ·· ··
Bronchopulmonary dysplasia|| 18/574 (3%) 17/580 (3%) 0·94 (0·49 to 1·78) 0·84 ·· ··
Brain injury on ultrasound scan** 34/574 (6%) 18/584 (3%) 0·50 (0·31 to 0·84) 0·008 ·· ··
Binary outcomes are n/N (%) and continuous outcomes are mean (SD). *CI for odds ratio (OR) and p value adjusted for multiple primary outcomes using Bonferroni-Holm method. †Median weeks of age 
at assessment: 111·6 weeks (IQR 104·6–122·2) in the placebo group and 110·4 weeks (104·0–121·5) in the progesterone group. ‡Sample size of 439 in the placebo group and 430 in the progesterone group 
and includes imputations for deaths. §Difference in means (95% CI). ¶Unadjusted for previous pregnancy of at least 14 weeks because of small sample size. ||Bronchopulmonary dysplasia deﬁ ned as need 
for at least 30% oxygen to maintain oxygen saturation above 92% or positive pressure (positive pressure ventilation or nasal continuous positive airway pressure) at 36 weeks postmenstrual age or 
discharge, whichever comes ﬁ rst. **Brain injury on ultrasound scan deﬁ ned as any intraventricular haemorrhage (excludes subependymal haemorrhages), parenchymal cystic or haemorrhagic lesion, or 
persistent ventriculomegaly (ventricular index >97th percentile); the components of the brain scan abnormalities were: intraventricular haemorrhage 13 (3%) of 383 patients and seven (2%) of 357 
patients, parenchymal cystic or haemorrhagic lesion 23 (6%) of 382 and eight (2%) of 357, and persistent ventriculomegaly (>97th percentile) eight (2%) of 372 and three (1%) of 349 in the placebo group 
and the progesterone group, respectively. 
Table 2: Primary outcomes and their components for women entered into the treatment phase of the OPPTIMUM study and their babies
Treatment eﬀ ect pinteraction
OR or mean diﬀ erence (95% CI); 
p value
N OR or mean diﬀ erence (95% CI); 
p value
N
Fibronectin status Negative Negative Positive Positive
Obstetric outcome 0·88 (0·58 to 1·33); 0·542 859 0·91 (0·57 to 1·46); 0·707 338 0·91
Neonatal outcome 0·65 (0·37 to 1·13); 0·129 847 0·64 (0·34 to 1·20); 0·162 329 0·96
Childhood outcome –0·63* (–3·28 to 2·03); 0·644 628 –1·09* (–5·41 to 3·23); 0·612 241 0·86
Cervical length at baseline >25 mm >25 mm ≤25 mm ≤25 mm
Obstetric outcome 0·88 (0·50 to 1·57); 0·672 445 0·69 (0·39 to 1·20); 0·191 251 0·54
Neonatal outcome 0·74 (0·35 to 1·56); 0·432 436 0·54 (0·25 to 1·16); 0·113 246 0·56
Childhood outcome –2·27* (–6·10 to 1·56); 0·247 317 –2·15* (–7·23 to 2·93); 0·408 179 0·97
Cervical length at baseline >15 mm >15 mm ≤15 mm ≤15 mm
Obstetric outcome 0·77 (0·48 to 1·23); 0·274 599 0·91 (0·41 to 2·04); 0·819 97 0·73
Neonatal outcome 0·73 (0·39 to 1·38); 0·334 588 0·49 (0·18 to 1·31); 0·156 94 0·50
Childhood outcome –2·49* (–5·77 to 0·78); 0·137 423 –0·69* (–8·60 to 7·22); 0·865 73 0·68
Chorioamnionitis No No Yes Yes
Obstetric outcome 1·38 (0·55 to 3·45); 0·497 115 2·17 (0·68 to 6·85); 0·190 57 0·55
Neonatal outcome 0·81 (0·22 to 2·96); 0·752 115 2·21 (0·76 to 6·40); 0·148 56 0·24
Childhood outcome –2·30* (–10·30 to 5·70); 0·575 81 –1·08* (–11·91 to 9·76); 0·846 43 0·86
History of spontaneous preterm birth No No Yes Yes
Obstetric outcome 0·99 (0·51 to 1·92); 0·972 273 0·82 (0·58 to 1·16); 0·254 903 0·62
Neonatal outcome 1·22 (0·55 to 2·71); 0·620 270 0·48 (0·29 to 0·79); 0·0042 886 0·053
Childhood outcome –1·11* (–5·96 to 3·73); 0·653 201 –0·14* (–2·79 to 2·52); 0·919 656 0·73
History of any preterm birth No No Yes Yes
Obstetric outcome 1·06 (0·53 to 2·12); 0·868 250 0·81 (0·58 to 1·14); 0·225 946 0·50
Neonatal outcome 1·09 (0·48 to 2·45); 0·836 248 0·52 (0·32 to 0·84); 0·0079 927 0·12
Childhood outcome –0·91* (–5·92 to 4·11); 0·724 187 –0·37* (–2·96 to 2·23); 0·782 681 0·85
Logistic or linear mixed eﬀ ects regression models predicting outcome from treatment, subgroup and the interaction of treatment with the subgroup variable, adjusting for 
previous pregnancy of at least 14 weeks and a random eﬀ ect for study centre. *Mean diﬀ erence. 
Table 3: Prespeciﬁ ed subgroup analyses based on baseline risk factors in women entered into the treatment phase of the OPPTIMUM study
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Placebo group Progesterone group OR, HR, or mean 
diﬀ erence (95% CI)
p value
N n (%) or mean 
(SD)
N n (%) or mean 
(SD)
Obstetric and neonatal
Gestational age at delivery (weeks) 597 36·8 (4·2) 600 36·9 (4·1) 1·03 (0·92 to 1·15) 0·62
Deaths up to 2 years of age 509 16 (3%) 500 20 (4%) 1·28* (0·66 to 2·51) 0·47
Death after trial entry up to end of study 598 16 (3%)† 600 20 (3%)† 1·26* (0·65 to 2·42) 0·5
Daily category of care after delivery room
Number of days of normal care 570 1·7 (2·3) 581 1·7 (1·6)
Number of days of special care 570 4·2 (10·6) 581 2·9 (8·3)
Number of days of high dependency care 569 2·2 (8·4) 580 2·1 (10·4)
Number of days intensive care 569 1·8 (7·3) 580 1·9 (8·1)
Surfactant administration 573 45 (8%) 583 47 (8%) 1·03 (0·68 to 1·55) 0·9
Suspected or conﬁ rmed necrotising entercolitis 574 13 (2%) 581 18 (3%) 1·37 (0·76 to 2·45) 0·29
Infections
Neonatal infection 573 36 (6%) 537 44 (8%) 1·22 (0·79 to 1·88) 0·36
One or more discrete episodes with positive blood culture among those with infection 33 19 (58%) 40 17 (42%) 0·51 (0·19 to 1·34) 0·18
One or more discrete episodes with positive CNS culture among those with infection 34 0 40 3 (7%) ‡ 0·25§
Maternal or child serious adverse event during pregnancy and birth 610 70 (11%) 616 59 (10%) 0·83 (0·58 to 1·16) 0·27
Childhood (2 years of age)
Health
Composite outcome of death or moderate-to-severe neurodevelopmental impairment at 
2 years
419 51 (12%) 399 67 (17%) 1·45 (0·98 to 2·15) 0·064
Moderate-to-severe neurodevelopmental impairment 403 35 (9%) 379 47 (12%) 1·48 (0·98 to 2·33) 0·087
Individual components of disability
Motor 456 4 (1%) 461 4 (1%) 0·99¶ (0·25 to 3·98) 0·99
Cognitive function 452 18 (4%) 461 19 (4%) 1·03 (0·58 to 1·84) 0·92
Hearing 465 2 (<1%) 466 1 (<1%) 0·56¶ (0·33 to 0·94) 0·028
Speech and language 446 14 (3%) 445 18 (4%) 1·32 (0·72 to 2·43) 0·36
Vision 466 4 (1%) 447 0 ‡ 0·13§
Respiratory 434 3 (1%) 413 7 (2%) 3·03¶ (1·56 to 5·88) 0·0011
Gastrointestinal 432 4 (1%) 412 9 (2%) 2·67¶ (1·37 to 5·20) 0·004
Renal 434 1 (<1%) 414 3 (1%) 3·65 (1·96 to 6·82) <0·0001
Admitted to hospital during follow-up 434 51 (12%) 416 48 (12%) 0·98 (0·65 to 1·47) 0·92
Behavioural scale scores at 2 years assessed in strengths and diﬃ  culties questionnaire||
Total diﬃ  culties 302 9·8 (4·9) 295 10·2 (4·9) 1·23 (0·85 to 1·78)**‡‡ 0·28
Emotional problems 341 1·1 (1·2) 328 1·1 (1·2) 1·01 (0·61 to 1·67)**‡‡ 0·96
Conduct problems 342 2·7 (1·8) 326 2·6 (1·8) 0·92 (0·65 to 1·31)**‡‡ 0·66
Hyperactivity scale 334 4·2 (2·4) 315 4·5 (2·3) 1·10 (0·79 to 1·55)**‡‡ 0·57
Peer problems scale 345 2·0 (1·7) 318 2·1 (1·6) 1·22 (0·88 to 1·69)**‡‡ 0·22
Prosocial scale 339 6·3 (2·2) 320 5·9 (2·3) 1·20 (0·88 to 1·63)**‡‡ 0·25
Impact scale 424 0·2 (1·0) 404 0·2 (1·2) 1·31 (0·73 to 2·35)**‡‡ 0·37
EQ-5D
Change in EQ-5D from baseline to birth 199 –0·023 (0·220) 191 –0·021 (0·207) 0·001§§ (–0·034 to 0·036) 0·97
Change in EQ-5D from baseline to 12 months 274 –0·015 (0·221) 279 –0·009 (0·213) 0·003§§ (–0·026 to 0·032) 0·83
Women’s views
Women’s perception of treatment 1 month post-delivery (proportion extremely or fairly 
satisﬁ ed)
327 314 (96·0) 307 294 (95·6) 0·93 (0·42 to 2·04) 0·85
*Hazard ratio (HR). †Median time to death: 759 days (range 1–1331) in the placebo group and 751 days (1–1335) in the progesterone group. ‡Regression failed with and without adjusting for previous 
pregnancy of more than 14 weeks. §Exact Fisher test. ¶Not adjusted for previous pregnancy of at least 14 weeks because regression failed. ||Mean age at assessment: 107·7 weeks (SD 17·7) in the placebo 
group and 106·9 weeks (17·1) in the progesterone group. **Score analysed as binary variable (raised compared with normal score). ‡‡Odds ratio (OR) of abnormal score. §§Mean diﬀ erence.
Table 4: Secondary outcomes
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outcome after the prespeciﬁ ed adjustment for multiple 
comparisons (Bonferroni-Holm procedure): OR 0·86 
(95% CI 0·61–1·22) for the obstetric outcome and OR 0·62 
(0·38–1·03) for the neonatal outcome (table 2). Similarly, 
there was no eﬀ ect on childhood outcomes (cognitive score 
97·7 [SD 17·5] for placebo and 97·3 [17·9] for progesterone; 
diﬀ erence in means –0·48, adjusted 95% CI –2·77 to 1·81).
Among the components of the primary obstetric and 
neonatal outcomes, the proportion of babies with 
observed neonatal brain injuries on cerebral ultrasound 
scanning was lower in the progesterone group (18 [3%] of 
584 vs 34 [6%] of 574; OR 0·50, 95% CI 0·31–0·84; 
table 2). A reduction in brain injury was also observed in 
a sensitivity analysis restricted to participants in whom a 
neonatal brain scan was done (n=776; OR 0·54, 95% CI 
0·32–0·88). Neonatal death was also less common in the 
progesterone group, but the low numbers precluded 
planned adjustment for the covariate previous pregnancy 
at 14 weeks or longer gestation.
Similar results for primary outcomes were achieved in 
per-protocol analyses (687 [56%] of 1226 patients in the 
intention-to-treat population; appendix); in analyses with 
multiple imputations of missing data on the primary 
outcomes (appendix); and in alternative multiple 
comparison procedures, including the Sidak-Holm 
method and permutation adjustment (50 000 permutations; 
data not shown). Comparison of characteristics of women 
included and not included in the per-protocol analysis are 
shown in the appendix. An additional sensitivity analysis 
with imputations for the variable smoking was done post 
hoc because of the diﬀ erence in smoking prevalence in 
those with and without outcome data: again this generated 
similar results to the main analysis (data not shown). A 
post-hoc survival curve of time to death or delivery (primary 
obstetric outcome) showed that the diﬀ erences between 
the progesterone and placebo groups appeared greatest at 
our prespeciﬁ ed gestational cutoﬀ  of 34 weeks (appendix).
Rates of preterm birth were higher in the predeﬁ ned 
subgroups of women with a positive fetal ﬁ bronectin 
test, women with a cervical length of at most 25 mm, 
and women with a cervical length of at most 
15 mm (appendix). However, there were no signiﬁ cant 
interactions between these groups and the eﬀ ect of 
progesterone on any of the obstetric, neonatal, or 
childhood outcomes. Within subgroups there was no 
signiﬁ cant eﬀ ect of progesterone on any of the primary 
obstetric or childhood outcomes (table 3). The interaction 
term approached statistical signiﬁ cance (p=0·053) for the 
neonatal outcome in the subgroup with a history of a 
previous spontaneous preterm birth, in which the OR for 
the neonatal outcome was lower in the progesterone 
group (0·48, 95% CI 0·29–0·79) compared with the 
complementary group with no previous spontaneous 
preterm birth (1·22, 0·55–2·71). However, caution is 
needed in interpreting all these ﬁ ndings given the 
number of prespeciﬁ ed subgroup analyses undertaken 
on three primary outcomes. 
Placebo group Progesterone group
N n (%) or mean (SD)* N n (%) or mean (SD)*
Pregnancy complications
Maternal
Obstetric cholestasis 589 6 (1%) 593 4 (1%)
Hypertension 590 24 (4%) 593 23 (4%)
Pre-eclampsia 590 11 (2%) 593 10 (2%)
Eclampsia 590 1 (<1%) 593 0
Preterm premature membrane rupture 590 72 (12%) 593 65 (11%)
Antepartum haemorrhage 590 36 (6%) 593 37 (6%)
Gestational diabetes 590 37 (6%) 593 27 (5%)
Conﬁ rmed deep vein thrombosis 590 2 (<1%) 593 0
Cervical cerclage 360 39 (11%) 368 41 (11%)
Other maternal complication 590 164 (28%) 593 166 (28%)
Fetal
Any 590 18 (3%) 593 19 (3%)
Abdominal circumference <5th percentile 18 4 (22%) 19 6 (32%)
Liquor volume reduced 18 6 (33%) 19 6 (32%)
Doppler >95th percentile (umbilical 
artery)
18 1 (6%) 19 1 (5%)
Absent end diastolic ﬂ ow (umbilical 
artery)
18 0 19 1 (5%)
Reversed end diastolic ﬂ ow (umbilical 
artery)
18 1 (6%) 19 1 (5%)
Abnormal antenatal CTG 18 7 (39%) 19 3 (16%)
Hospital admissions
Antenatal hospital admissions per woman
Mean (SD) 581 0·7 (1·3) 579 0·6 (1·1)
Median (range) 581 0 (0–10) 579 0 (0–8)
Hospital admissions for threatened 
preterm labour
581 132 (23%) 579 119 (21%)
With tocolysis 581 18 (3%) 579 15 (3%)
With steroid 581 71 (12%) 579 80 (14%)
With antibiotic 581 52 (9%) 579 38 (7%)
With cervical cerclage 581 10 (2%) 579 8 (1%)
With magnesium sulfate 581 0 579 0
Women with antenatal hospital 
admission for other reasons
581 135 (23%) 579 107 (18%)
Labour
Duration of ﬁ rst stage (h) 463 4·1 (5·1) 470 4·3 (5·3)
Duration of second stage (min) 462 47·0 (132·8) 471 41·2 (91·6)
Duration of third stage (min) 465 17·0 (46·2) 477 16·1 (51·6)
Artiﬁ cial rupture of membranes performed 468 131 (28%) 448 122 (27%)
Analgesia in labour (any) 576 455 (79%) 574 478 (83%)
General anaesthetic 576 16 (3%) 574 12 (2%)
Epidural 576 191 (33%) 574 197 (34%)
Opiates 576 88 (15%) 574 88 (15%)
Nitrous oxide 576 269 (47%) 574 303 (53%)
Other 576 34 (6%) 574 31 (5%)
Delivery method
Spontaneous vaginal delivery 578 380 (66%) 576 375 (65%)
LSCS in labour 578 58 (10%) 576 57 (10%)
LSCS pre-labour 578 92 (16%) 576 84 (15%)
Forceps 578 21 (4%) 576 27 (5%)
(Table 5 continues on next page)
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Most of the other secondary outcomes did not diﬀ er 
statistically between progesterone and placebo groups 
(table 4). Although neurodevelopmental impairments 
were similarly distributed in each group, somatic 
impairments in renal, gastrointestinal, and respiratory 
systems though of low frequency, were more common in 
the progesterone group. There were no apparent 
diﬀ erences in the proportions with safety or other 
outcomes between the placebo and progesterone groups 
(table 5).
Discussion
OPPTIMUM is the largest randomised trial of vaginal 
progesterone for prevention of preterm birth in women at 
high risk. By contrast with published reports,13–15 we show 
no eﬀ ect of progesterone on rates of either preterm birth 
or neonatal composite outcome. For the ﬁ rst time using a 
direct assessment, we provide strong evidence that the 
use of progesterone from 22–24 to 34 gestational weeks 
has no demonstrable eﬀ ect on 2 year neuro developmental 
outcomes, either as cognitive scores or impairments, 
suggesting that progesterone prophylaxis to prevent 
preterm birth appears safe for the baby (at least up to 
2 years of age). Only one previous study has determined 
long-term eﬀ ects of progestogens given to singleton 
pregnancies in a randomised trial of intra muscular 
17α-hydroxyprogesterone caproate,16,17 but this study used 
parent report and had a smaller sample size with a higher 
proportion lost to follow-up. The other published studies 
are restricted to questionnaire or health record-based 
assessments in twins whose mothers were enrolled in 
randomised trials of progesterone versus placebo.18,19
OPPTIMUM was a pragmatic trial, set up to examine 
eﬀ ects of progesterone on outcomes in a heterogeneous 
group of women at risk of preterm birth. We extended 
our recruitment criteria early in the study, when newly 
available information suggested we were missing women 
at high risk of preterm birth. Notably, the ﬁ bronectin-
negative group recruited under the extended criteria, had 
rates of the primary outcome (death or preterm birth 
before 34 weeks) of 13% (appendix), some three times 
those of the background population of pregnant women 
in the UK.20 Hence, our decision to extend the recruitment 
criteria appears correct. Importantly, although we were 
able to deﬁ ne at baseline subgroups of women with 
higher rates of preterm birth (including those with a 
short cervix and those with a positive ﬁ bronectin test), 
our data suggest that the eﬃ  cacy of progesterone (for all 
outcomes) is similar across groups. Therefore, our data 
do not support the premise that vaginal progesterone is 
speciﬁ cally eﬀ ective in women with a short cervix.
Although we showed no overall eﬀ ect, point estimates 
of the reduction in the odds of the obstetric outcome 
(0·86) and the neonatal composite outcome (0·62) are in 
the direction of beneﬁ t, but with CIs that show no 
advantage. Additionally, point estimates in the short 
cervix subgroups are similar to those reported in meta-
analyses of the eﬀ ect of progesterone in such women. 
For example, the OR for preterm birth prevention was 
0·69 in OPPTIMUM, compared with a RR of 0·64 
(before 34 weeks) in one systematic review 21 and a RR of 
0·58 (before 33 weeks) in an individual patient data 
meta-analysis.1 The corresponding ﬁ gures for eﬀ ects on a 
neonatal composite are OR 0·54 in OPPTIMUM and 
RR 0·57 in the individual patient data meta-analysis.1 An 
individual patient data meta-analysis, including the 
OPPTIMUM ﬁ ndings, to understand what the totality of 
evidence indicates, particularly within subgroups of 
interest, is likely to be helpful. 
 Although we have shown no signiﬁ cant eﬀ ect on the 
overall neonatal composite outcome, there appeared to be 
a reduction in neonatal brain injury. Progesterone-associated 
reduction in brain injury is plausible given supportive 
preclinical data in adult models showing potentially 
neuroprotective eﬀ ects of reduced inﬂ ammatory cytokine 
production, reduced activation of microglial cells, and 
limited apoptosis,22,23 although a recent trial of over 
1000 adult participants with traumatic brain injury has 
shown no clinical therapeutic eﬀ ect.24 However, in the 
absence of long-term improvements in cognitive function, 
Placebo group Progesterone group
N n (%) or mean (SD)* N n (%) or mean (SD)*
(Continued from previous page)
Ventouse 578 18 (3%) 576 20 (3%)
Vaginal breech (spontaneous or assisted) 578 9 (2%) 576 13 (2%)
Blood loss (mL) 572 387 (356) 572 424 (394)
Blood transfusion 578 10 (2%) 574 18 (3%)
Antibiotics during labour and delivery 578 96 (17%) 573 92 (16%)
Surgical procedure required 578 15 (3%) 575 18 (3%)
Mean duration of hospital stay (days) 577 3·2 (2·2) 567 3·3 (4·1)
Median duration of hospital stay, days 
(range)
577 3·0 (1·0–19·0) 567 3·0 (1·0–86·0)
Any post-partum complication 580 83 (14%) 577 90 (16%)
Placental examination
No evidence of infection 84 57 (68%) 83 56 (67%)
Chorioamnionitis 84 10 (12%) 83 9 (11%)
Chorioamnionitis and funisitis 84 17 (20%) 83 18 (22%)
Birth outcomes
Male sex† 578 289 (50%) 578 293 (51%)
Birthweight (g) 577 2822 (884) 577 2875 (847)
Median Apgar score at 1 min (IQR) 553 9·0 (8·0–9·0) 557 9·0 (8·0–9·0)
Median Apgar score at 5 min (IQR) 555 9·0 (9·0–10·0) 560 9·0 (9·0–10·0)
Median length of hospital stay, days (IQR) 556 2·0 (1·0–6·0) 562 2·0 (1·0–4·0)
Outcomes at 2 years
Weight (kg) 355 13·2 (2·6) 332 13·4 (2·7)
Height (cm) 369 87·2 (10·7) 347 87·4 (7·9)
Head circumference (cm) 354 48·9 (4·6) 332 49·6 (6·7)
*Data are n (%) or mean (SD), unless otherwise stated. Outcomes in the safety population (ie, women who took at 
least one tablet of placebo or progesterone). CTG=cardiotocograph. LSCS=lower segment caesarean section. †One 
baby of indeterminate sex in the progesterone group.
Table 5: Safety outcomes
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a protective eﬀ ect of progesterone on brain injury (deﬁ ned 
by ultrasound) might not be important clinically: not only 
was brain injury on ultrasound a relatively rare event in 
OPPTIMUM but other studies have shown no correlation 
between this ﬁ nding and longer term neurosensory 
impairment.25 Additionally, these non-signiﬁ cant red-
uctions in the neonatal composite adverse outcome need 
to be considered against the non-signiﬁ cant increase in the 
childhood adverse outcome of death or moderate-to-severe 
neurodevelopmental impairment.
OPPTIMUM strongly suggests that the eﬃ  cacy of 
progesterone in improving outcomes is either non-
existent or weak. Given the heterogeneity of the preterm 
labour syndrome we cannot exclude beneﬁ t in speciﬁ c 
phenotypic or genotypic subgroups of women at risk. 
However, the subgroups of women who might beneﬁ t do 
not appear to be easily identiﬁ able by current selection 
strategies, including cervical length measurement and 
ﬁ bronectin testing. 
Reassuringly, our study suggests that progesterone is 
safe for those who wish to take it for preterm birth 
prophylaxis. The overall rate of maternal or child adverse 
events was similar in the progesterone and placebo groups. 
There were few diﬀ erences in the incidence of adverse 
secondary outcomes in the two groups, with the exception 
of a higher rate of renal, gastrointestinal, and respiratory 
complications in childhood in the progesterone groups. 
Importantly, the absolute rates of these complications was 
low. Follow-up of other babies exposed in utero to vaginal 
progesterone would be helpful in determining whether the 
increased rate of some renal, gastrointestinal, and 
respiratory complications is a real eﬀ ect or a type I error. 
A potential weakness in our trial is that overall 
compliance was only 69%. This contrasts with a reported 
compliance of 88·5% in the study by Hassan and 
colleagues,13 but is greater than the compliance seen in 
routine clinical practice.26 Additionally, the assumption 
in the Hassan study that women who did not return 
study medication were fully compliant might have 
erroneously inﬂ ated their estimate of compliance. No 
information on compliance was reported in the other 
large study on vaginal progesterone in singletons.15 
Notably, in OPPTIMUM, the eﬀ ect size for each of the 
primary outcomes was very similar in the per-protocol 
analysis (restricted to those with adequate treatment 
compliance) compared with the intention-to-treat group, 
suggesting that suboptimum compliance did not have a 
major eﬀ ect on overall results. 
We believe that OPPTIMUM should prompt a major 
review of the use of progesterone for preterm birth 
prophylaxis, a search to identify speciﬁ c women who 
might speciﬁ cally beneﬁ t, and a redoubling of eﬀ orts to 
ﬁ nd alternative strategies to prevent preterm birth in 
women at risk. For those clinicians and women who 
wish still to use progesterone for preterm birth 
prophylaxis, our data provide reassurance that it appears 
safe, at least until 2 years of age of the child. 
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